Key Details
Price
$191.89Annual ROE
12.78%Beta
1.02Events Calendar
Next earnings date:
Feb 05, 2025Recent quarterly earnings:
Nov 06, 2024Recent annual earnings:
Nov 06, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Feb 28, 2006Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
WARREN, N.J., Jan. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) has announced that on January 3, 2025, it granted 1,200 restricted stock units (RSUs) to two new employees. Each RSU gives the right to receive one share of the company's common stock once it vests.
PTC Therapeutics, Inc. announced that their total revenue for 2024 is around $814 million, which is higher than expected. They have submitted four applications for approval to the FDA this year and are preparing to launch sepiapterin for PKU, targeting a market worth $1 billion, with expected opinions and decisions in 2025. Additionally, they have finalized a collaboration agreement with Novartis for the PTC518 program, with data results anticipated in the second quarter of 2025.
PTC announced FQ4 2024 results that were better than anticipated, but it is struggling with revenue growth because of external challenges and changes in its marketing strategy. The worldwide PLM market is expected to grow at a rate of 9.2% annually until 2030, fueled by the demand for cloud-based systems and smart products. While PTC's financial performance has improved in terms of operating income and gross margins, its revenue growth in international markets, especially in Europe, is not keeping pace.
WARREN, N.J., Dec. 23, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) has announced today that their CEO, Matthew B.
Everyone is aware of how artificial intelligence (AI) and wireless digital technologies are becoming more important in our everyday lives. However, many people may not realize the significant impact these changes are having on the manufacturing sector and how an industrial software company like PTC is involved in this transformation.
If it gets the green light, vatiquinone will be the first and only approved treatment for children with Friedreich ataxia (FA). This marks PTC's fourth application for approval submitted to the FDA in 2024. On December 19, 2024, PTC Therapeutics, Inc. announced that they have submitted the New Drug Application (NDA) for vatiquinone to treat both children and adults with FA.
WARREN, N.J., Dec. 17, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that on December 13, 2024, it granted non-statutory stock options for a total of 1,725 shares of its common stock and 5,060 restricted stock units (RSUs) to eight new employees. Each RSU will convert into one share of common stock once it vests.
BOSTON, Dec. 9, 2024 /PRNewswire/ -- PTC (NASDAQ: PTC) has announced the appointment of Robert Dahdah as Executive Vice President and Chief Revenue Officer. Dahdah previously worked at Microsoft as the Corporate Vice President for Global Healthcare and Life Sciences.
PTC has teamed up with Microsoft and Volkswagen to create an AI Copilot called Codebeamer, which aims to make product development easier.
A collaboration has been formed between industry leaders to enhance the use of generative AI in manufacturing. The Codebeamer Copilot is designed to make managing requirements easier during product development, with a beta version expected to launch in early 2025. This tool will help software engineers work more effectively by allowing them to create, manage, test, and validate product requirements.
FAQ
- What is the primary business of PTC?
- What is the ticker symbol for PTC?
- Does PTC pay dividends?
- What sector is PTC in?
- What industry is PTC in?
- What country is PTC based in?
- When did PTC go public?
- Is PTC in the S&P 500?
- Is PTC in the NASDAQ 100?
- Is PTC in the Dow Jones?
- When was PTC's last earnings report?
- When does PTC report earnings?
- Should I buy PTC stock now?